Designation supports phase 3 launch in watch-and-wait patients in 2026
Category: News
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers
Three-year partnership to expand at-home health checks and vaccination access via NHS App
Linzagolix with add-back Therapy accepted for use within NHS Scotland
Blenrep combination offers improved survival for those ineligible for lenalidomide
Dutch biotech’s ORE-001 shows strong potential to prevent ileus after major surgery
New MHRA–FDA collaboration aims to boost patient access and AI safety
Positive safety and pharmacokinetic data lay foundation for phase 2 study in 2026
